Table 1.

Summary of article content

Section	Key points	References
1	Current diagnostic tools in early detection and treatment options for ovarian cancer patients are still very limited	[12-16]
	High recurrence rate of chemoresistant ovarian cancer has been associated with self-renewing ovarian cancer stem cells (OCSCs)	[27-40]
	Multiple mechanisms have been identified for OCSCs associated chemoresistance	[41-66]
2	Several clinical trials to treat ovarian cancer patients with oncolytic viruses have been initiated in recent years	[67-82]
3	Viruses that have been shown to have the potential of eradicating CSCs include adenovirus (Ads), herpes simplex virus-1 (HSV-1), vaccinia virus (VV), myxoma virus (MYXV), reovirus, measles virus (MV), Newcastle disease virus (NDV), and Maraba virus (MRBV)	[8, 83-98]
4	Vesicular stomatitis virus (VSV) is newly emerging and promising oncolytic agent for cancer treatment. Defects in innate immune responses involving the interferon (IFN) system and dysregulated translation machinery may contribute to VSV's intrinsic, oncolytic properties Several approaches have been undertaken to improve safety and selectivity of VSV	[99-137]
5	Efficacy of VSV in ovarian cancer mouse models varied considerably. Discrepancies in the outcome in these models may be related to the differences within tumors	[139-140, 142, 145-152]
6	The potential oncolytic effectiveness of VSV should be evaluated in newly emerged experimental models (in vivo or in vitro) that recapitulate different aspects of human ovarian cancer such as fallopian tube origins and ovarian cancer spheroids	[153-171]